Peak night to watch the Lyrid Meteor Shower
SAN ANGELO, Texas (Concho Valley Homepage) — Experts say to look toward the East on April 21 around midnight to see the Lyrid Meteor Shower.
'The Lyrids are sort of centered in the constellation of Lyra,' said ASU Planetarium Director Kenneth Carrell. 'Lyra is actually pretty easy to find because the Star Vega is in the constellation of Lyra.'
The star Vega is the brightest in the summertime night sky, and can be seen now around 11 p.m.
'You can look over in the east sometime around midnight or so, you should see a fairly bright star start to rise in the constellation of Lyra,' Carrell said.
The meteors are from a comet that passes by the Earth about every 400 years.
Carrell says that the ASU planetarium will be showing two new shows on campus.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Bird flu can live in raw milk for more than a week, study finds
The bird flu virus can remain infectious in raw milk for over a day at room temperature and more than a week when refrigerated, according to a new, non-peer-reviewed research from a group of UK scientists. The study, published in medRxiv, examined the stability of the H5N1 avian influenza virus in raw cow and sheep milk, with researchers simulating storage conditions common in dairy settings. 'High viral titres were detected in milk from infected cows, raising concerns about onwards human infections,' the authors wrote. Scientists emphasized that pasteurization effectively kills the virus, but unpasteurized milk poses a potential risk of infection, both through occupational exposure in dairies and the consumption of raw milk. To test how long the virus remains infectious, scientists incubated the virus in pasteurized milk at room temperature and at 39.2 F, simulating both ambient dairy conditions and refrigerated storage. They also tested sheep's milk using a lab strain of avian flu. Scientists stressed that these results represent a 'worst-case scenario' and are meant to provide an 'upper-bound' estimate of how long H5N1 might survive in milk. They urged continued precautions to reduce zoonotic transmission risks. Bird flu has devastated poultry and dairy farms, and sent the price of eggs soaring in the U.S. since it was first detected in North America in late 2021. More than 12,000 individual birds have tested positive since the virus began spreading, according to the Agriculture Department. The Associated Press contributed to this report. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
5 hours ago
- Yahoo
Musk says SpaceX will no longer decommission Dragon spacecraft despite Trump feud
Elon Musk said Thursday he changed his mind about decommissioning SpaceX's Dragon spacecraft after a user on the social platform X suggested he 'cool off and take a step back' amid his public blowout with President Trump. 'Ok we won't decommission Dragon,' Musk wrote Thursday night in response to the user. Just hours earlier, Musk said SpaceX, his aerospace company, would ground Dragon, the spacecraft NASA uses to service the International Space Station. 'In light of the President's statement about cancellation of my government contracts, @SpaceX will begin decommissioning its Dragon spacecraft immediately,' Musk said Thursday afternoon. Musk's post included a screenshot of a threat from Trump to eliminate billions of dollars in federal contracts and subsidies the tech billionaire's companies receive. But by Thursday night, the blowout appeared to be calming down. One X user replied to Musk's afternoon post, 'This is a shame this back and forth. You are both better than this. Cool off and take a step back for a couple days.' Musk replied, 'Good advice,' and said he would not decommission Dragon. Dragon, as described by SpaceX, is the 'only spacecraft currently flying that is capable of returning significant amounts of cargo to Earth and is the first private spacecraft to take humans to the space station.' Musk's change of mind was a relief for many in the aerospace community, as NASA has become increasingly reliant on SpaceX for space operations. The decommissioning of Dragon could risk the Trump administration's ability to bring astronauts and cargo back and forth between the space station and Earth. NASA press secretary Bethany Stevens said in a post on X that the agency 'will continue to execute upon the President's vision for the future of space. We will continue to work with our industry partners to ensure the President's objectives in space are met.' The back-and-forth came amid a broader feud between Musk and Trump. At one point, Musk accused Trump of being listed in the classified files related to Jeffrey Epstein. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
9 hours ago
- Yahoo
Rectify Pharma Presents Translational Data Demonstrating Improvements in Kidney Function and Reductions in Vascular Calcification at ERA 2025
Potent, selective ABCC6-targeting positive functional modulator (PFM) improved multiple markers of renal function in animal models of chronic kidney disease (CKD) PFM improved inorganic pyrophosphate (PPi) efflux via on-target engagement of the ABCC6 membrane transporter and reduced vascular calcification in animal models of CKD BOSTON, June 06, 2025 (GLOBE NEWSWIRE) -- Rectify Pharmaceuticals, Inc., ('Rectify') a biotechnology company pioneering positive functional modulators (PFMs) that restore and enhance membrane protein function, today showcased new data from its cardiorenal program with its ABCC6-targeting PFM, RTY-822. The results were presented in an oral presentation during the European Renal Association (ERA) 2025 Congress, taking place in Vienna, Austria, June 4 – 7, 2025. 'These translational results demonstrate that Rectify's PFM reduces vascular calcification and kidney injury and improves kidney function through enhancement of ABCC6 function,' said Rajesh Devraj, Ph.D., President and Chief Executive Officer of Rectify. 'We believe the strength of these data underscores the potential of our approach to offer a novel and differentiated therapeutic strategy to treat renal dysfunction and injury, as well as address vascular calcification driving cardiovascular disease. We are committed to continuing to advance meaningful therapies for patients with CKD and serious cardiovascular conditions.' Robert Hughes, Ph.D., Chief Scientific Officer of Rectify, added, 'Enhancing the function of ABCC6 holds the potential to address key drivers of vascular calcification and tubular dysfunction seen in CKD. With demonstrated on-target engagement, RTY-822 shows significant promise to reduce CKD-associated calcium deposits in arterial walls, a well-established contributor to cardiovascular morbidity and mortality seen in patients with CKD, and remarkably, also improves glomerular function and tubular injury. The translational readiness of this program makes it a compelling de-risked asset with the potential to address CKD and multiple cardiovascular indications.' Title: A Positive Functional Modulator of ABCC6 Decreases Vascular Calcification and Improves Kidney Function in a Rat Adenine Diet Model of Chronic Kidney DiseaseAbstract Number: 1723 Presenter: John Miller, Ph.D. Session: Chronic Kidney Disease, Focused Oral Room 4Date and Time: Friday, June 6, 2025, 8:51 a.m. – 8:57 a.m. CEST In CKD, reduced ABCC6 activity or expression may lead to lower PPi levels, contributing to pathological calcification in blood vessels and kidneys. Restoring ABCC6 function or enhancing its expression offers a new and compelling therapeutic strategy to prevent the progression of CKD towards end-stage renal disease in addition to reducing large vessel calcification, a major driver of cardiovascular complications in CKD. Key findings RTY-822, an orally administered PFM targeting ABCC6 increased both ABCC6 protein expression and plasma PPi levels in primary human hepatocytes, supporting its proposed mechanism of action In a rat model of CKD and vascular calcification induced by an adenine-enriched diet with calcitriol supplementation: RTY-822 treatment led to statistically significant reductions in vascular calcification in the aorta and the femoral arteries After a six-week treatment course, RTY-822 improved glomerular and tubular kidney functions, with statistically significant reductions in serum creatinine, urea, and cystatin C, and an improved estimated glomerular filtration rate (eGFR) Calcium accumulation in the kidney was also significantly reduced Kidney injury biomarkers were reduced, including a significant decrease in plasma KIM-1 and urinary Lipocalin-2 (NGAL) levels In rats fed an adenine-rich diet without calcitriol supplementation, treatment with RTY-822 resulted in: Improved glomerular and tubular kidney functions Reduced serum creatinine and cystatin C levels Increased eGFR Reduced urinary NGAL levels, a biomarker of acute kidney injury The presentation is available on the Rectify website at About Rectify Pharmaceuticals, Inc. ('Rectify') Rectify is advancing Positive Functional Modulators (PFMs), a novel class of oral, small molecules that restore and enhance membrane protein function to address the underlying cause of serious diseases. Rectify's PFMs have potential to modulate the activity of wild-type and mutated membrane-bound proteins, a historically difficult challenge with a small molecule approach. The Company's breakthrough product platform enables efficient and rapid discovery of first- and best-in-class small molecule therapies with the potential to address membrane protein dysfunction for treatment of rare and common diseases, including liver, cardio-renal-metabolic, and neurodegenerative diseases. Rectify was founded and seeded by Atlas Venture who co-led the $100M Series A round with Omega Funds and were joined by Forbion and Longwood Fund. For more information, please visit or follow us on X and LinkedIn. ContactMediaJonathan PappasLifeSci Communicationsjpappas@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
